Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Products under Development by Stage of Development | 8 | 1 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Products under Development by Therapy Area | 9 | 1 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Products under Development by Indication | 10 | 1 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Products under Development by Companies | 13 | 2 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Products under Development by Universities/Institutes | 15 | 2 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Companies Involved in Therapeutics Development | 23 | 7 |
| 3SBio Inc. | 23 | 1 |
| Amgen Inc. | 24 | 1 |
| Eisai Co., Ltd. | 25 | 1 |
| Intas Pharmaceuticals Ltd. | 26 | 1 |
| Novartis AG | 27 | 1 |
| Shionogi &Co., Ltd. | 28 | 1 |
| STATegics, Inc. | 29 | 1 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Drug Profiles | 30 | 20 |
| avatrombopag Drug Profile | 30 | 2 |
| eltrombopag olamine Drug Profile | 32 | 6 |
| eltrombopag olamine Drug Profile | 38 | 1 |
| GSK-2285921 Drug Profile | 39 | 2 |
| lusutrombopag Drug Profile | 41 | 1 |
| Monoclonal Antibody to Agonize TpoR for Thrombocytopenia Drug Profile | 42 | 1 |
| romiplostim Drug Profile | 43 | 3 |
| romiplostim biosimilar Drug Profile | 46 | 1 |
| STST-4 Drug Profile | 47 | 1 |
| thrombopoietin Drug Profile | 48 | 1 |
| thrombopoietin Drug Profile | 49 | 1 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Dormant Projects | 50 | 1 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Discontinued Products | 51 | 1 |
| Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c-Mpl or CD110 or MPL) Featured News &Press Releases | 52 | 15 |
| Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder | 52 | 1 |
| May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association | 53 | 1 |
| Apr 19, 2016: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia | 54 | 2 |
| Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP | 56 | 1 |
| Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag | 57 | 1 |
| Dec 01, 2015: Shionogi Launches MULPLETA Tablets 3mg In Japan for Improvement of Thrombocytopenia | 58 | 1 |
| Sep 28, 2015: Shionogi Receives Marketing and Manufacturing Approval in Japan for MULPLETA Tablets 3mg for Improvement of Thrombocytopenia | 58 | 1 |
| Sep 02, 2015: Novartis receives EU approval for new Revolade use as first-in-class therapy for patients with severe aplastic anemia | 59 | 1 |
| Aug 24, 2015: FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia | 60 | 1 |
| Jul 24, 2015: Novartis drug Revolade recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder | 61 | 1 |
| Jun 12, 2015: FDA Approves Promacta for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication | 62 | 1 |
| Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder | 63 | 2 |
| May 27, 2015: Amgen To present data from Nplate study at the 20th Congress of the EHA | 65 | 1 |
| Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) | 65 | 1 |
| Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta) | 66 | 1 |
| Appendix | 67 | 2 |
| Methodology | 67 | 1 |
| Coverage | 67 | 1 |
| Secondary Research | 67 | 1 |
| Primary Research | 67 | 1 |
| Expert Panel Validation | 67 | 1 |
| Contact Us | 67 | 1 |
| Disclaimer | 68 | 1 |